Amylyx Pharmaceuticals, Inc.
AMLX
$14.05
$0.261.89%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -665.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -665.00K |
| Cost of Revenue | -62.23M | 19.86M | 27.22M | 22.12M | -72.43M |
| Gross Profit | 62.23M | -19.86M | -27.22M | -22.12M | 71.77M |
| SG&A Expenses | 15.39M | 16.17M | 15.64M | 15.68M | 17.10M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 36.61M | 36.03M | 42.86M | 37.80M | 39.99M |
| Operating Income | -36.61M | -36.03M | -42.86M | -37.80M | -40.65M |
| Income Before Tax | -32.95M | -34.39M | -41.44M | -35.91M | -38.18M |
| Income Tax Expenses | 46.00K | -- | -- | -- | -635.00K |
| Earnings from Continuing Operations | -33.00M | -34.39M | -41.44M | -35.91M | -37.55M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -33.00M | -34.39M | -41.44M | -35.91M | -37.55M |
| EBIT | -36.61M | -36.03M | -42.86M | -37.80M | -40.65M |
| EBITDA | -36.50M | -35.91M | -42.72M | -37.65M | -40.49M |
| EPS Basic | -0.30 | -0.37 | -0.46 | -0.42 | -0.55 |
| Normalized Basic EPS | -0.22 | -0.23 | -0.29 | -0.26 | -0.44 |
| EPS Diluted | -0.30 | -0.37 | -0.46 | -0.42 | -0.55 |
| Normalized Diluted EPS | -0.22 | -0.23 | -0.29 | -0.26 | -0.44 |
| Average Basic Shares Outstanding | 109.84M | 93.33M | 89.14M | 85.70M | 68.59M |
| Average Diluted Shares Outstanding | 109.84M | 93.33M | 89.14M | 85.70M | 68.59M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |